Locations:

Multiple Sclerosis

23-NEU-3839387-stiff-curved-back-650×450

May 12, 2023/Neurosciences/Multiple Sclerosis

Unique Database Yields Insights Into Familial Clustering in Stiff-Person Spectrum Disorder

Mounting evidence of possible shared genetic predisposition

brain MRI showing central vein sign in a patient with multiple sclerosis

May 5, 2023/Neurosciences/Multiple Sclerosis

The Case for Including the Central Vein Sign in the Next Diagnostic Criteria for Multiple Sclerosis

Biomarker promises a practical way to reduce misdiagnoses

April 26, 2023/Neurosciences/Multiple Sclerosis

Shorter Ocrelizumab Infusion Time for Multiple Sclerosis Does Not Affect Safety Profile

No notable difference in reactions with two-hour infusion in ENSEMBLE PLUS substudy

February 6, 2023/Neurosciences/Multiple Sclerosis

It’s Time for a New Framework for Characterizing Multiple Sclerosis

A focus on biological processes should improve both research and management

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

22-NEU-3409067_central-vein-sign_650x450

December 8, 2022/Neurosciences/Multiple Sclerosis

Central Vein Sign on FLAIR* MRI Comparable to CSF Oligoclonal Bands for Diagnosing MS

Initial pilot study findings suggest a potential reduced need for cerebrospinal fluid testing

October 28, 2022/Health Information Technology

Leveraging Telehealth to Provide Comprehensive Multiple Sclerosis Care

NIH grant supports longitudinal study of clinical, cost and patient/clinician experience outcomes

22-NEU-3222062_mesenchymal-stem-cells_650x450

September 20, 2022/Neurosciences/Multiple Sclerosis

Phase 2 Trial Hints at Promise of Cellular Therapy for Progressive MS

Single-arm, open-label study offers proof of concept for MSC-NTF cells

22-NEU-2902059_multiple-sclerosis_650x450

June 22, 2022/Neurosciences/Multiple Sclerosis

Phase 2 Data Show Vidofludimus Calcium Suppresses MRI Lesions in Relapsing MS With Good Tolerability

Selective DHODH inhibitor designed as a better-tolerated alternative to teriflunomide

March 17, 2022/Neurosciences/Multiple Sclerosis

Three Standout Investigations at ACTRIMS 2022

Research avenues to keep an eye on in MS and NMOSD diagnostics and therapeutics

March 11, 2022/Neurosciences/Multiple Sclerosis

Multiple Sclerosis and Cannabis Use: Where Do Patients Get Their Information?

Survey suggests need for evidence-based education among patients and providers alike

BackPage 3 of 5Next